Funding agencies: The Goldwurm site acknowledges the funding support of the Italian Telethon Foundation (grant no.: GTB07001) and the “Fondazione Grigioni per il Morbo di Parkinson.” The Maraganore site acknowledges the funding support of the National Institutes of Health (R01 ES10751). The Morrison site acknowledges the funding support of the Medical Research Council UK, Midlands Neuroscience Teaching and Research Fund, and Queen Elizabeth Hospital Birmingham Charity. The Theuns/Van Broeckhoven site acknowledges the funding support of the Interuniversity Attraction Poles program of the Belgian Science Policy Office, the Foundation for Alzheimer Research, the Belgian Parkinson Foundation, the Methusalem Excellence Program of the Flemish Government, the Research Foundation Flanders, the Agency for Innovation by Science and Technology Flanders, and the Special Research Fund of the University of Antwerp, Antwerp, Belgium. The Wszolek site acknowledges the funding support of the National Institutes of Health (P50 NS072187) and the Mayo Clinic Florida Research Committee CR program.
Alpha-synuclein repeat variants and survival in Parkinson's disease
Article first published online: 27 FEB 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 8, pages 1053–1057, July 2014
How to Cite
Chung, S. J., Biernacka, J. M., Armasu, S. M., Anderson, K., Frigerio, R., Aasly, J. O., Annesi, G., Bentivoglio, A. R., Brighina, L., Chartier-Harlin, M.-C., Goldwurm, S., Hadjigeorgiou, G., Jasinska-Myga, B., Jeon, B. S., Kim, Y. J., Krüger, R., Lesage, S., Markopoulou, K., Mellick, G., Morrison, K. E., Puschmann, A., Tan, E.-K., Crosiers, D., Theuns, J., Van Broeckhoven, C., Wirdefeldt, K., Wszolek, Z. K., Elbaz, A., Maraganore, D. M. and on behalf of the Genetic Epidemiology of Parkinson's Disease Consortium (2014), Alpha-synuclein repeat variants and survival in Parkinson's disease. Mov. Disord., 29: 1053–1057. doi: 10.1002/mds.25841
Relevant conflicts of interest/financial disclosures: Demetrius M. Maraganore, MD has licensed an invention to Alnylam Pharmaceuticals, Inc. regarding a method to treat Parkinson's disease. He has received less than $25,000 in royalties. The remaining authors have nothing to declare.
- Issue published online: 17 JUL 2014
- Article first published online: 27 FEB 2014
- Manuscript Accepted: 20 JAN 2014
- Manuscript Revised: 15 JAN 2014
- Manuscript Received: 9 AUG 2013
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.